Literature DB >> 10478487

Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O'-alkyl analogues.

B Kierdaszuk1, K Krawiec, Z Kazimierczuk, U Jacobsson, N G Johansson, B Munch-Petersen, S Eriksson, D Shugar.   

Abstract

Nucleoside analogues with modified sugar moieties have been examined for their substrate/inhibitor specificities towards highly purified deoxycytidine kinase (dCK) and thymidine kinases (tetrameric high-affinity form of TK1, and TK2) from human leukemic spleen. In particular, the analogues included the mono- and di-O'-methyl derivatives of dC, dU and dA, syntheses of which are described. In general, purine nucleosides with modified sugar rings were feebler substrates than the corresponding cytosine analogues. Sugar-modified analogues of dU were also relatively poor substrates of TK1 and TK2, but were reasonably good inhibitors, with generally lower Ki values vs TK2 than TK1. An excellent discriminator between TK1 and TK2 was 3'-hexanoylamino-2',3'-dideoxythymidine, with a Ki of approximately 600 microM for TK1 and approximately 0.1 microM for TK2. 3'-OMe-dC was a superior inhibitor of dCK to its 5'-O-methyl congener, consistent with possible participation of the oxygen of the (3')-OH or (3')-OMe as proton acceptor in hydrogen bonding with the enzyme. Surprisingly alpha-dT was a good substrate of both TK1 and TK2, with Ki values of 120 and 30 microM for TK1 and TK2, respectively; and a 3'-branched alpha-L-deoxycytidine analogue proved to be as good a substrate as its alpha-D-counterpart. Several 5'-substituted analogues of dC were good non-substrate inhibitors of dCK and, to a lesser extent, of TK2. Finally, some ribonucleosides are substrates of the foregoing enzymes; in particular C is a good substrate of dCK, and 2'-OMe-C is an even better substrate than dC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478487     DOI: 10.1080/07328319908044850

Source DB:  PubMed          Journal:  Nucleosides Nucleotides        ISSN: 0732-8311


  6 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer.

Authors:  Haihao Sun; Andrew Sloan; Thomas J Mangner; Ulka Vaishampayan; Otto Muzik; Jerry M Collins; Kirk Douglas; Anthony F Shields
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01       Impact factor: 9.236

3.  2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread.

Authors:  Jeffrey J Bajramovic; Romain Volmer; Sylvie Syan; Sylvie Pochet; Daniel Gonzalez-Dunia
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 4.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

5.  Semi-Automated High-Throughput Substrate Screening Assay for Nucleoside Kinases.

Authors:  Katja F Hellendahl; Maryke Fehlau; Sebastian Hans; Peter Neubauer; Anke Kurreck
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 6.  Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future.

Authors:  María-Jesús Pérez-Pérez; Eva-María Priego; Ana-Isabel Hernández; Olga Familiar; María-José Camarasa; Ana Negri; Federico Gago; Jan Balzarini
Journal:  Med Res Rev       Date:  2008-09       Impact factor: 12.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.